{"organizations": [], "uuid": "61420b8e11de97fb00817a9fb7e5eac6bd023b72", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-arena-pharma-and-outpost-medicine/brief-arena-pharma-and-outpost-medicine-enter-into-licensing-agreement-for-undisclosed-novel-compound-idUSFWN1S807X", "country": "US", "domain_rank": 408, "title": "BRIEF-Arena Pharma And Outpost Medicine Enter Into Licensing Agreement For Undisclosed Novel Compound", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-01T15:59:00.000+03:00", "replies_count": 0, "uuid": "61420b8e11de97fb00817a9fb7e5eac6bd023b72"}, "author": "", "url": "https://www.reuters.com/article/brief-arena-pharma-and-outpost-medicine/brief-arena-pharma-and-outpost-medicine-enter-into-licensing-agreement-for-undisclosed-novel-compound-idUSFWN1S807X", "ord_in_thread": 0, "title": "BRIEF-Arena Pharma And Outpost Medicine Enter Into Licensing Agreement For Undisclosed Novel Compound", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-arena pharma and outpost medicine enter into lic", "sentiment": "negative"}, {"name": "arena pharmaceuticals inc", "sentiment": "none"}, {"name": "reuters staff", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 1, 2018 / 1:01 PM / Updated 9 minutes ago BRIEF-Arena Pharma And Outpost Medicine Enter Into Licensing Agreement For Undisclosed Novel Compound Reuters Staff\nMay 1 (Reuters) - Arena Pharmaceuticals Inc:\n* ARENA PHARMACEUTICALS AND OUTPOST MEDICINE ENTER INTO LICENSING AGREEMENT FOR UNDISCLOSED NOVEL COMPOUND\n* ARENA PHARMACEUTICALS - WILL GET UPFRONT FEE COMPRISED OF CASH AND EQUITY TOTALING $3.0 MILLION\n* ARENA PHARMACEUTICALS - ELIGIBLE TO GET ABOUT $100 MILLION IN MILESTONE PAYMENTS AS PART OF DEAL\n* ARENA - CO, OUTPOST MEDICINE TO ADVANCE UNDISCLOSED, PRECLINICAL COMPOUND WITH POTENTIAL UTILITY IN TREATING GENITOURINARY DISORDERS\n* ARENA - COMPOUND THAT IS PART OF DEAL WITH OUTPOST MEDICINE TARGETS UNDISCLOSED G PROTEIN-COUPLED RECEPTOR , WAS INTERNALLY DISCOVERED BY ARENA Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-05-01T15:59:00.000+03:00", "crawled": "2018-05-01T16:14:38.005+03:00", "highlightTitle": ""}